Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Breast Cancer

Presenters

Ho-hyun Ryu

Citation

Annals of Oncology (2019) 30 (suppl_9): ix9-ix12. 10.1093/annonc/mdz417

Authors

H. Ryu1, S.H. Ahn2, B.H. Son2, J.W. Lee2, B.S. Ko2, J. Kim2, I.Y. Chung3, H. Kim2

Author affiliations

  • 1 Depariment Of Surgery, Division Of Breast Surgery, Asan Medical Center - University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 2 Division Of Breast Department Of Surgery, Asan Medical Center - University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 3 Breast Surgery, Asan Medical Center - Asan Institute for Life Science, 138-736 - Seoul/KR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 30P

Background

Survival of breast cancer has improved and treatment related metabolic profile deterioration after neoadjuvant systemic treatment (NST) becomes important issues in cancer survivors. We sought to compare metabolic and immune changes in patients who underwent 6 months of neoadjuvant chemotherapy (NCT) and neoadjuvant endocrine therapy (NET).

Methods

Prospective, randomized, phase III trial (NEST) which compared 24 weeks of response of NCT with Adriamycin and cyclophosphamide followed by docetaxel and NET with goserelin and tamoxifen. Among them, 123 patients from NEST trial in Asan Medical Center were retrospectively reviewed to evaluate metabolic changes such as BMI, total cholesterol (TC), fasting glucose and blood pressure (BP) before/after NST and 3 years of follow up. NLR were checked before and after NST. WHO classification was used for BMI and BP was classified according to 2017 AHA guideline.

Results

The mean age of patients was 42 years old. Overweight group were significantly increased after NCT and recovered after 3 year follow up (8.2%, 12.0%, 6.9% respectively, p < 0.05). BMI changes were not observed in NET group (time p value= 0.110). The mean value of initial TC before NCT was 184.6mg/dL, 216.0 mg/dL after NCT (p < 0.05), 179.0 mg/dL after 3 years of treatment (p < 0.05, after vs 3 yrs.). In the NET group, the mean initial TC before NET was 185.0mg/dL, and decreased to 176.3 mg/dL after NET, and 179.4 mg/dL after 3 yrs follow up (p = 0.192). In the NCT group, the mean fasting glucose were significantly increased while NCT (95.2mg/dL to 108.8mg/dL, p < 0.05), and recovered after 3 year follow up (98.0 mg/dL, p < 0.05). In the NET group, the mean fasting glucose changes were not observed (97.0mg/dL, 98.4 mg/dL and 98.4 mg/dL respectively p > 0.05, all). There are no effect on HTN during NCT and NET (p > 0.05 respectively). NLR was increased from 2.0 to 4.4 after NCT (p < 0.05) and decreased from 2.1 to 1.6(p < 0.05) after NET.

Conclusions

Compared with no changes on NET, NCT causes worsening of metabolic profiles such as BMI, TC, and fasting glucose, which is recovered over 3 years. NLR was increased after NCT but decreased after NET.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.